THU0178 Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib

Background Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines (eg interleukin [IL]-2, -4, -7, -15, -21) involved in lymphocyte development, function and homeostasis are known to signal through JAK. Objectives To characterise changes in natural killer (NK) cell counts following tofacitinib treatment and evaluate the relationship between NK counts and rates of infection and malignancy. Methods Lymphocyte subset data, enumerated by flow cytometric analyses, were pooled from 3 double-blind, placebo-controlled, Phase 2 (P2) studies (two monotherapy and one background methotrexate [MTX]) in MTX inadequate responders, and from a sub-study of an ongoing long-term extension (LTE) study (study is ongoing; database not locked). RA patients (pts) received tofacitinib (1 to 30 mg twice daily [BID]) or placebo for 6 to 24 weeks in P2 and tofacitinib 5 or 10 mg BID for 22 months (median) in LTE. 928 and 161 pts contributed NK cell data in P2 and LTE, respectively. Correlations between baseline or nadir NK cell count and serious infection (SIE, any infection that requires hospitalisation for treatment or parenteral antimicrobial therapy), herpes zoster (HZ) and malignancy (excluding non-melanoma skin cancer) were assessed by sub-dividing NK cell data into deciles and calculating incidence rate (events/100 pt-years) of adverse events for each decile. Results Following tofacitinib administration, NK cell counts decreased in a dose-dependent manner by Week 2 (Figure 1A). Median NK cells counts returned to baseline 2 to 6 weeks after treatment discontinuation (dc). At the 5 mg BID dose, pts with the largest (>90th percentile) decrease in NK cell counts recovered from ∼70% below baseline to ∼18% by 6 weeks after treatment dc (n=4). The estimated median decrease for 5 mg BID at Week 24 was ∼35%. Cross-sectional analyses in different groups of pts showed similar median NK cell count in the LTE (141 cells/μL) compared to pre-treatment baseline (135 cells/μL). No clear association between baseline or nadir NK cell counts (predominantly collected within first 6 months of treatment) and the incidence of SIE, HZ or malignancy (Figure 1B) was seen over the period of observation (median duration 1.9 years). Conclusions Tofacitinib treatment is associated with a dose-dependent decrease in NK cell counts. No association between baseline or nadir NK cell counts and the incidence of SIE, HZ or malignancy was observed. Long-term lymphocyte subset data are being collected in the ongoing LTE study to confirm these relationships. Acknowledgements Previously presented (van Vollenhoven R et al. Arthritis Rheum 2014; 66(11): S220 abs 508) and reproduced with permission from Arthritis and Rheumatism. All aspects of this work were funded by Pfizer Inc. Editorial support under the direction of the authors was provided by Amanda Pedder, of Complete Medical Communications, and funded by Pfizer Inc. Disclosure of Interest R. F. van Vollenhoven Grant/research support from: Pfizer, Consultant for: Pfizer, Y. Tanaka Consultant for: Abbvie, Chugai, Astellas, Takeda, Santen, Mitsubishi Tanabe, Pfizer, Janssen, Eisai, Daiichi-Sankyo, UCB Japan, GlaxoSmithKline, Bristol-Myers Squibb, Speakers bureau: Abbvie, Chugai, Astellas, Takeda, Santen, Mitsubishi Tanabe, Pfizer, Janssen, Eisai, Daiichi-Sankyo, UCB Japan, GlaxoSmithKline, Bristol-Myers Squibb, M. Lamba Shareholder of: Pfizer, Employee of: Pfizer, M. Collinge Shareholder of: Pfizer, Employee of: Pfizer, T. Hendrikx Employee of: Pfizer, T. Hirose Shareholder of: Pfizer, Employee of: Pfizer Japan, S. Toyoizumi Employee of: Pfizer Japan, A. Hazra Shareholder of: Pfizer, Employee of: Pfizer, S. Krishnaswami Shareholder of: Pfizer, Employee of: Pfizer